Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in sales and operating profit for the first nine months of 2024. Sales rose by 23% in Danish kroner and 24% at constant exchange rates (CER) to DKK 204.7 billion, while operating profit grew by 21% in Danish kroner and 22% at CER to DKK 91.6 billion. The growth was primarily driven by the Diabetes and Obesity care segment, with GLP-1 diabetes sales increasing by 25% in Danish kroner and Obesity care growing by 44% to DKK 43.7 billion. North America Operations saw a 31% increase in sales, with the US market contributing significantly to this growth. The company also completed several clinical trials, including the phase 2a trial with monlunabant in obesity, and announced positive results from the...Show More

Novo Nordisk A/S, a leading global healthcare company, reported a significant increase in sales and operating profit for the first nine months of 2024. Sales rose by 23% in Danish kroner and 24% at constant exchange rates (CER) to DKK 204.7 billion, while operating profit grew by 21% in Danish kroner and 22% at CER to DKK 91.6 billion. The growth was primarily driven by the Diabetes and Obesity care segment, with GLP-1 diabetes sales increasing by 25% in Danish kroner and Obesity care growing by 44% to DKK 43.7 billion. North America Operations saw a 31% increase in sales, with the US market contributing significantly to this growth. The company also completed several clinical trials, including the phase 2a trial with monlunabant in obesity, and announced positive results from the SOUL cardiovascular outcomes trial with oral semaglutide. Novo Nordisk expects to initiate a phase 2b trial in obesity in 2025. For the full year 2024, Novo Nordisk now expects sales growth to be between 23-27% at CER and operating profit growth to be between 21-27% at CER. The company's CEO, Lars Fruergaard Jørgensen, expressed satisfaction with the performance and highlighted the increasing demand for GLP-1-based diabetes and obesity treatments. An earnings call was held on November 6, 2024, to discuss these results.